매출 하락 → 마진 압박 → 현금 악화
Critical매출이 -1.9% 감소하며 영업이익률이 -330.5%에서 -348.7%로 하락했다. 영업현금흐름도 동반 감소하여 수익-현금 순환이 약화되고 있다.
Evidence
매출 YoY -1.9% (2024→2025)영업이익률 -330.5%→-348.7%영업CF -10→-10
Intelligent Bio Solutions
INBS · Nasdaq$2.23-3.04%
2026-09-04 closeIntelligent Bio Solutions last closed at $2.23 (-3.04%) on 2026-09-04. Listed on Nasdaq; price, financials and dividends update daily after market close.
Loading chart…
Close
No active signal.
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
277 picks
Next-day win rate
44.2%
Avg next-day
-0.28%
vs market
-0.51%p
Every new-high-plus-volume pick we actually published (US market) — not this stock alone.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
F
Overall: 건강관리 726/745 · top 97%
Factor composite · relative position in sector
PER — · PBR 0.71 — own-history percentile 4/100 · 75/100
Open self-history band
PER4/100
PBR75/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Financial safety
Reference indicatorAs of 2025Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -33.75
Distress
Grey
Safe
- Altman Z''
- -33.75
- Beneish M-Score
- -2.44
- Sloan accrual
- -10.81%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
2/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score2/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverPass
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -317%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Margin trendWarning
영업이익률 악화 (-330.5% → -348.7%, -18.3%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
USAs of 2026-09-05건강관리
This stock is in 건강관리: revenue rank 466 of 543, share 0%.
466 / 5430%revenue share
Who dominates this industry?
- 1CVS Health14.1%
- 2McKesson13.6%
- 3Cigna9.4%
- 4Cardinal Health8.4%
- 5Centene6.2%
- 6Intelligent Bio Solutions0%
Concentration
DistributedCR3 37.1%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 159.97
- Direction
- 축소
- Level
- 넓음
- Years
- 21
Value lens
- P90/P10
- 24.4
- Median P/B
- 3.02
- Level
- 넓음
- n
- 463
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -348.7%
- Interest coverage
- -174.8x
- Return on equity (ROE)
- -352.7%
Operating margin −5pp
Operating lossInterest coverageBase -174.8x adverse case -177.3x
Return on equity (ROE)Base -352.7% adverse case -362.4%
Revenue −15%
Interest coverage riskInterest coverageBase -174.8x adverse case -148.6x
Return on equity (ROE)Base -352.7% adverse case -304%
Interest rate +2pp
Interest coverage riskInterest coverageBase -174.8x adverse case -64.1x
Return on equity (ROE)Base -352.7% adverse case -360.8%
Interest coverage limit
Already below the limit by 350.7ppInterest coverage limit at an operating margin of 2%
Interest expense coverage threshold
Recent filings
Filings for overseas stocks are on the way. For now we cover Korean stocks only.
About Intelligent Bio Solutions
- What technical signals does Intelligent Bio Solutions (INBS) have?
- Intelligent Bio Solutions current technical signals: no active technical signal.
- Is Intelligent Bio Solutions a cup-and-handle pattern?
- No. Intelligent Bio Solutions has no valid cup-and-handle signal right now.
- What are Intelligent Bio Solutions's financials and valuation?
- Intelligent Bio Solutions's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy